Navigation Links
Lilly Receives NCQA Design Certification for Depression Care Management Program
Date:11/6/2007

INDIANAPOLIS, Nov. 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) has received Program Design Certification from the National Committee for Quality Assurance (NCQA) for its Tools that Empower(TM) Depression Care Management Program.

Tools that Empower(TM) Depression Care Management Program is designed for managed care organizations to assist in further driving the standard of patient care around Major Depressive Disorder (MDD). Lilly created the program in response to the growing population of patients diagnosed with MDD.

Developed by experts in MDD management, including practicing psychiatrists and psychologists, clinical research experts, managed care medical directors and mental health specialty physicians, Tools that Empower helps identify members with MDD and offers educational resources to support treatment. In addition, the program helps enroll members, perform clinical screening and clinical risk stratification; offers interventions based on member clinical risk; executes program satisfaction assessment and outcomes measurement; and provides a comprehensive list of MDD resources.

The foundation of this program is based upon the APA Standards of Care for major depressive disorder, the HEDIS(R) measure for Antidepressant Medication Management, and several other related, peer-reviewed articles.

NCQA certification is an indication that a disease management program has passed a rigorous review in a specific area, either program design, patient contact or disease management systems. According to NCQA, certification standards are purposely set high to encourage organizations to continuously enhance their quality.

"Disease management offers tremendous promise for improving the care received by the chronically ill," said Margaret E. O'Kane, president of NCQA. "By achieving NCQA DM Certification, an organization is showing that it is ready to provide specific services that can help fulfill that promise."

Offering relevant, non-branded interventions that are based on the most recent clinical research and findings is an example of how Lilly seeks to meet the needs of patients.

"Tools that Empower is part of Lilly's commitment to our customers to help reduce patient risk and create an environment of continuous improvement for patient care," said Jack Bailey, vice president, Lilly's Business to Business division. "The NCQA certification validates the helpful tools provided by the program."

Disease Management Certification is based on a review of disease management content - such as printed, electronic and in-person methods for working with patients and practitioners - according to clinical guidelines. NCQA has reviewed and certified Lilly's Program Design capability. For complete details on the scope of this review, visit http://www.lilly.com.

Lilly also offers several other NCQA Design Certified programs as part of its ongoing commitment to improving patient safety and quality. They include:

-- Tools That Empower(TM) Diabetes Management Program, a robust diabetes

disease management program that contains more than 20 best-in-class

tools and resources for care managers and diabetes program directors.

-- HealthInsights for Women, a disease management program that targets

women 30 years and older about disease risk factors, and inspires them

to make behavior changes that can lead to better health.

-- Health Evaluator for Lilly Partners (HELP), a comprehensive,

interactive online resource for patients that is flexible, customizable

and secure.

-- Expanding Views: Achieving more with ADHD, reinforces the importance

of providing follow-up care for patients with

attention-deficit/hyperactivity disorder (ADHD) based upon the HEDIS(R)

measure.

About NCQA:

NCQA is a private, non-profit organization dedicated to improving healthcare quality. NCQA is committed to providing healthcare quality information through the Web and the media in order to help consumers, employers and others make more informed healthcare choices.

Consumers can access an organization's NCQA Accreditation and Certification status and other information on healthcare quality on NCQA's Web site at http://www.ncqa.org, or by calling NCQA Customer Support at (888) 275-7585.

About Lilly:

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

HEDIS (Healthcare Effectiveness Data and Information Set) is a registered trademark of the National Committee for Quality Assurance. Tools that Empower is a trademark of Eli Lilly and Company.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... BioSciences, Inc. (NASDAQ: SGMO ), the leader ... quarter and full year 2015 financial results and ... editing," said Edward Lanphier, Sangamo,s president and chief ... leads the therapeutic genome editing field and we ... our ground-breaking genome editing programs through IND enabling ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
(Date:2/9/2016)... --  AllCare Plus Pharmacy announced today that it ... ® for Home Care Accreditation by ... Seal of Approval ® is a symbol of ... and effective care.  --> ... on-site survey in January 2016. The survey reflected compliance ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when ... president of the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and ... goals are cast aside. , That’s why one of her first decisions when her ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... businesses recover after a disaster, announced today the acquisition of Hawaii DKI. Hawaii ... , “Investing in like-minded companies who excel at service and response ...
(Date:2/9/2016)... MA (PRWEB) , ... February 09, 2016 , ... ... (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for a ... services covered in the report, Evaluation of the 2015 Fee Schedule Rates ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), ... the ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient ... , “Since our Pay It Forward program began, we are proud to ...
(Date:2/9/2016)... ... 2016 , ... The Journal of Pain Research has published the ... , As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention ... pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the ...
Breaking Medicine News(10 mins):